# 2026-20141: FDA greenlights skin/eye drug advisors through 2028

2026-20141, Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-10-01, effective Authority for the Dermatologic and Ophthalmic Drugs Advisory Committee will expire on October 7, 2026, unless the Commissioner formally determines that renewal is in the public interest. (as of 2026-10-08).

- Canonical: https://policyrisk.com/federal-register/2026-20141
- As of: 2026-10-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20141
- Title: Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 62530
- Published: 2026-10-01
- Effective: Authority for the Dermatologic and Ophthalmic Drugs Advisory Committee will expire on October 7, 2026, unless the Commissioner formally determines that renewal is in the public interest.
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-10-08

## In one line

FDA greenlights skin/eye drug advisors through 2028

## Summary

The FDA is renewing the Dermatologic and Ophthalmic Drugs Advisory Committee for two more years, keeping it active until October 7, 2028. This committee helps make sure skin and eye medicines are safe and effective, affecting patients, doctors, and drug makers. No new costs or big changes, just a green light to keep the expert advice coming!

## Abstract

The Food and Drug Administration (FDA) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2028, expiration date.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20141 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/01/2026-20141/advisory-committee-dermatologic-and-ophthalmic-drugs-advisory-committee-renewal)
- [2026-20141 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-01/pdf/2026-20141.pdf)

## Related
- [Previous: 2026-20139, Aluminum Foil From Armenia, Brazil, Oman, Russia, and Turkey; Institution of Fi…](https://policyrisk.com/federal-register/2026-20139)
- [Next: 2026-20142, Advisory Committee; Antimicrobial Drugs Advisory Committee; Renewal](https://policyrisk.com/federal-register/2026-20142)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20141 (as of 2026-10-08).
